Core Viewpoint - Yiju Medical (06929) reported a revenue of $83.55 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.88% [1] - The profit attributable to shareholders for the period was $19.785 million, an increase of 5.08% year-on-year, with basic earnings per share at 2.4 cents [1] - The company proposed a special dividend of 15 Hong Kong cents (approximately 1.92 US cents) per share [1] Group Performance - Despite tariff disruptions, the company achieved strong year-on-year growth in the U.S. market, indicating robust demand for its quality products [1] - Emerging markets, particularly in the Asia-Pacific region and Europe, the Middle East, and Africa, have shown positive trends, becoming the main growth engines in the first half of the year [1] - However, the growth was partially offset by a decrease in sales in the Japanese market and a decline in average selling prices in the Chinese market [1] Financial Analysis - The net profit growth was primarily driven by an increase in foreign exchange gains and a reduction in income tax expenses [1] - This growth was partially countered by a decrease in interest income and an increase in sales and marketing expenses [1]
业聚医疗发布中期业绩，股东应占利润1978.5万美元，同比增加5.08%